<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2207245620
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Mictonorm XL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PROPIVERINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Modified-release capsule, soft
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        150.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LOSAN PHARMA GMBH " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LOSAN PHARMA GMBH 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Labatec- Pharma S.A
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BD06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Mictonorm XL is used for the treatment of people who have difﬁculty in controlling their bladders due to bladder overactivity. Mictonorm XL contains the active substance Propiverine hydrochloride. This substance prevents the bladder from contracting and increases the amount that the bladder can hold. Mictonorm XL is used to treat the symptoms of overactive bladder. It is a modiﬁed-release capsule that needs only to be taken once a day.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Mictonorm XL if</strong></p><p>You are allergic (hypersensitive) to propiverine hydrochloride or any of the other ingredients of this medicine (listed in section 6)</p><p><strong>Contents of the pack and other information</strong></p><p>(allergic reactions include mild symptoms such as itching and/or rash. More severe symptoms include swelling of the face, lips, tongue and/or throat with difﬁculty in swallowing or breathing)</p><p><strong>Do not take Mictonorm XL if you have</strong></p><p>&middot; &nbsp;Obstruction of the bowel</p><p>&middot; &nbsp;Obstruction to the bladder outlet (difﬁculty in passing urine)</p><p>&middot; &nbsp;Myasthenia gravis (a disease-causing muscle weakness)</p><p>&middot; &nbsp;A loss of function of the muscles controlling your bowel movements (intestinal atony)</p><p>&middot; &nbsp;Severe inﬂammation of the bowel (ulcerative colitis) that may lead to diarrhea containing blood and mucus and abdominal</p><p>&nbsp;pains</p><p>&middot; &nbsp;Toxic megacolon (a condition involving enlargement of the bowel)</p><p>&middot; &nbsp;Increased pressure in the eye (uncontrolled angle closure glaucoma)</p><p>&middot; &nbsp;Moderate or severe liver disease</p><p>&middot; &nbsp;Fast or irregular heartbeat</p><p><strong>Warnings and precautions:</strong></p><p>Talk to your doctor or pharmacist or nurse before taking Mictonorm XL if you have.</p><p>&middot; &nbsp;Damage to the nerves that control blood pressure, heart rate, bowel and bladder movement and other bodily functions (autonomic neuropathy)</p><p>&middot; &nbsp;Liver problems</p><p>&middot; &nbsp;Kidney problems</p><p>&middot; &nbsp;Severe heart failure</p><p>&middot; &nbsp;Enlargement of the prostate gland</p><p>&middot; &nbsp;Recurrent urinary tract infection</p><p>&middot; &nbsp;Tumors of the urinary tract</p><p>&middot; &nbsp;Glaucoma</p><p>&middot; &nbsp;Heartburn and indigestion due to back ﬂow of gastric juice into the throat (hiatus hernia with reﬂux esophagitis)</p><p>&middot; &nbsp;Irregular heartbeat</p><p>&middot; &nbsp;Fast heartbeat</p><p>If you suffer from any of these conditions, contact your doctor. He will tell you what to do.</p><p><strong>Other medicines and Mictonorm XL</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any of the following medicines as they may interact with Mictonorm XL.</p><p>&middot; Antidepressants (e.g. imipramine, clomipramine, amitriptyline)</p><p>&middot; Sleeping tablets (e.g. benzodiazepines)</p><p>&middot; Anticholinergics taken by mouth or injection (usually used to treat asthma, stomach cramps, eye problems or urinary incontinence)</p><p>&middot; Amantadine (used to treat ﬂu and Parkinson&rsquo;s disease)</p><p>&middot; Neuroleptics such as promazine, olanzapine, quetiapine (drugs used to treat psychotic disorders like schizophrenia and anxiety)</p><p>&middot; Beta stimulants (drugs used to treat asthma)</p><p>&middot; Cholinergics (e.g. carbachol and pilocarpine)</p><p>&middot; Isoniazid (a treatment for tuberculosis)</p><p>&middot; Metoclopramide (used to treat nausea and vomiting)</p><p>&middot; Concomitant treatment with methimazole (used to treat hyperfunction of the thyroid gland) and medicines used to treat fungal diseases (e.g. ketoconazole, itraconazole)</p><p>Nevertheless, it may still be all right for you to take Mictonorm XL. Your doctor will be able to decide what is suitable for you.</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p><strong>Pregnancy and breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Do not take Mictonorm XL if you are pregnant, likely to become pregnant or are breast-feeding.</p><p><strong>Driving and using machines</strong></p><p>Mictonorm XL can sometimes cause sleepiness and blurred vision. You should not drive or operate machinery until you are sure you are not affected.</p><p><strong>Mictonorm XL contains lactose (a sugar)</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>The recommended dosage is</strong></p><p>Adults and the elderly: the recommended dose is one capsule daily.</p><p><strong>Use in children and adolescents</strong></p><p>Mictonorm XL is not recommended for children.</p><p><strong>Method of administration</strong></p><p>Take your capsule at the same time each day. Swallow the capsule whole with a drink of water. Do not crush or chew the capsules. You may take them with or without food.</p><p><strong>If you take more Mictonorm XL than you should</strong></p><p>If you have accidentally taken more than your prescribed dose, contact your nearest casualty department or tell your doctor or pharmacist immediately. Remember to take the pack and any remaining capsules with you. Overdosage can cause symptoms such as restlessness, dizziness, disorders in speech and vision, muscular weakness, dry mouth, faster heartbeat and problems passing urine.</p><p><strong>If you forget to take Mictonorm XL</strong></p><p>Do not worry. Simply leave out that dose completely. Then take your next dose at the right time. Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>All medicines can cause allergic reactions although serious allergic reactions are very rare.</p><p>The following symptoms are ﬁrst signs for such reactions:</p><p>&middot; Any sudden wheeziness, difﬁculty in breathing or dizziness, swelling of the eyelids, face, lips or throat.</p><p>&middot; Peeling and blistering of the skin, mouth, eyes and genitals.</p><p>&middot; Rash affecting your whole body.</p><p>If you get any of these symptoms during treatment, you should stop taking the capsules and contact your doctor immediately.</p><p>You might suffer an acute attack of glaucoma. If you have been seeing colored rings around lights or if you should develop severe pain in and around eye <strong>you should seek medical attention urgently.</strong></p><p>The following side effects have been reported:</p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><p>Dry mouth.</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p>Abnormal vision and difﬁculty in focusing, fatigue, headache, abdominal pain, indigestion, constipation.</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>Feeling sick and vomiting, dizziness, trembling (tremor), inability to empty the bladder (urinary retention), ﬂushing, altered sense of taste, decreased blood pressure with drowsiness, itching, difﬁculty in passing urine.</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>Rash.</p><p>Faster heartbeat.</p><p><strong>Very Rare (may affect up to 1 in 10,000 people)</strong></p><p>Feeling your heartbeat, restlessness and confusion.</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>Sensing things that are not real (hallucinations).</p><p>Speech disorder.</p><p>All possible side effects are transient and recede after a dose reduction or termination of the therapy after maximum 1-4 days.</p><p>During long-term therapy hepatic enzymes should be monitored, because reversible changes of liver enzymes might occur in rare cases.</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaﬂet. Any suspected or adverse event on this product should be reported to drugsafety@labatec.com.</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacis</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot; Keep this medicine out of sight and reach of children.</p><p>&middot; Do not store the blister pack above 30&deg;C.</p><p>&middot; Keep the capsules in the original package to protect from moisture.</p><p>&middot; Do not use this medicine after the expiry date which is stated on the carton.</p><p>&middot; The expiry date refers to the last day of that month.</p><p>&middot; Do not throw away any medicines via wastewater or household waste.</p><p>&middot; Ask your pharmacist how to throw away medicines you no longer use.</p><p>&middot; These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is propiverine hydrochloride. Each modiﬁed release capsule contains 30 mg of propiverine hydrochloride.</p><p>The other ingredients are citric acid, povidone, lactose monohydrate, talc, triethyl citrate, magnesium stearate, methacrylic acid-methyl methacrylate copolymer (1:1 and 1:2), ammonio methacrylate copolymer (type A and B), gelatin, titanium dioxide (E171), red iron oxide (E17 2) and yellow iron oxide (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Available in pharmacy with medical prescription.
Mictonorm XL capsules are available in boxes of 7 (7's Blister x 1) and 28 (7's Blister x 4) capsules in blister packs.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufacturer:</p><p>Losan Pharma GmbH, Otto-Hahn-Stra&szlig;e 13, 79395 Neuenburg, Germany</p><p>Marketing Authorization Holder</p><p>Labatec Pharma SA, 1217 Meyrin (Geneva), Switzerland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in (12/2022)
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ﯾﺳﺗﺧدم ميكتونورم إكس إل ﻟﻌﻼج اﻷﺷﺧﺎص اﻟذﯾن ﯾﺟدون ﺻﻌوﺑﺔ ﻓﻲ اﻟﺗﺣﻛم ﻓﻲ اﻟﻣﺛﺎﻧﺔ ﺑﺳﺑب ﻓرط ﻧﺷﺎط اﻟﻣﺛﺎﻧﺔ. ﯾﺣﺗوي ميكتونورم إكس إل ﻋﻠﻰ اﻟﻣﺎدة اﻟﻔﻌﺎﻟﺔ ﺑروﺑﯾﻔﯾرﯾن ھﯾدروﻛﻠورﯾد. ھذه اﻟﻣﺎدة ﺗﻣﻧﻊ اﻟﻣﺛﺎﻧﺔ ﻣن اﻻﻧﻘﺑﺎض وﺗزﯾد ﻣن اﻟﻛﻣﯾﺔ اﻟﺗﻲ ﯾﻣﻛن أن ﺗﺣﺗﻔظ ﺑﮭﺎ اﻟﻣﺛﺎﻧﺔ. ﯾﺳﺗﺧدم ميكتونورم إكس إل ﻟﻌﻼج أﻋراض ﻓرط ﻧﺷﺎط اﻟﻣﺛﺎﻧﺔ. إﻧﮭﺎ ﻛﺑﺳوﻟﺔ ﻣﻌدﻟﺔ اﻟﻣﻔﻌول ﻻ ﺗﺣﺗﺎج إﻟﻰ ﺗﻧﺎوﻟﮭﺎ إﻻ ﻣرة واﺣدة ﻓﻲ اﻟﯾوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ميكتونورم إكس إل إذا:-</strong></p><p dir="RTL">ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﺣﺳاﺳﯾﺔ ﺗﺟﺎه ﺑروﺑﯾﻔﯾرﯾن ھﯾدروﻛﻠورﯾد أو أي ﻣن اﻟﻣﻛوﻧﺎت اﻷﺧرى ﻟﮭذا اﻟدواء اﻟﻣدرﺟﺔ ﻓﻲ اﻟﻘﺳم 6.</p><p dir="RTL"><strong>ﻣﺣﺗوﯾﺎت اﻟﻌﺑوة وﻣﻌﻠوﻣﺎت أﺧرى</strong></p><p dir="RTL">(تشمل ردود اﻟﻔﻌل اﻟﺗﺣﺳﺳﯾﺔ أﻋراﺿًﺎ ﺧﻔﯾﻔﺔ ﻣﺛل اﻟﺣﻛﺔ و / أو اﻟطﻔﺢ اﻟﺟﻠدي. ﺗﺷﻣل اﻷﻋراض اﻷﻛﺛر ﺣدة ﺗورم الوجه واﻟﺷﻔﺗﯾن واﻟﻠﺳﺎن و / أو اﻟﺣﻠق مع ﺻﻌوﺑﺔ ﻓﻲ اﻟﺑﻠﻊ أو اﻟﺗﻧﻔس).</p><p dir="RTL"><strong>لا تتناول ميكتونورم إكس إل :-</strong></p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك اﻧﺳداد ﻓﻲ اﻷﻣﻌﺎء.</p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك اﻧﺳداد ﻓﻲ ﻣﺧرج اﻟﻣﺛﺎﻧﺔ )ﺻﻌوﺑﺔ ﻓﻲ اﻟﺗﺑول(.</p><p dir="RTL">&middot; إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن اﻟوھن اﻟﻌﺿﻠﻲ اﻟﺷدﯾد )ﻣرض ﯾﺳﺑب ﺿﻌف اﻟﻌﺿﻼت(.</p><p dir="RTL">&middot; إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻓﻘدان وظﯾﻔﺔ اﻟﻌﺿﻼت اﻟﺗﻲ ﺗﺗﺣﻛم ﻓﻲ ﺣرﻛﺎت اﻷﻣﻌﺎء )وﻧﻰ اﻷﻣﻌﺎء(.</p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك اﻟﺗﮭﺎب ﺷدﯾد ﻓﻲ اﻷﻣﻌﺎء )اﻟﺗﮭﺎب اﻟﻘوﻟون اﻟﺗﻘرﺣﻲ (اﻟذي ﻗد ﯾؤدي إﻟﻰ إﺳﮭﺎل ﯾﺣﺗوي ﻋﻠﻰ دم&nbsp; وﻣﺧﺎط وآﻻم ﻓﻲ اﻟﺑطن.</p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك ﺗﺿﺧم اﻟﻘوﻟون اﻟﺳﺎم )ﺣﺎﻟﺔ ﺗﺷﻣل ﺗﺿﺧم اﻷﻣﻌﺎء(.</p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك ﺿﻐط ﻣﺗزاﯾد ﻓﻲ اﻟﻌﯾن) زرق اﻟﻌﯾن ﻏﯾر اﻟﻣﻧﺿﺑط(.</p><p dir="RTL">&middot; إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻣرض ﻛﺑدي ﻣﺗوﺳط أو ﺷدﯾد.</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﺿرﺑﺎت ﻗﻠب ﺳرﯾﻌﺔ أو ﻏﯾر ﻣﻧﺗظﻣﺔ.</p><p dir="RTL"><strong>المحاذير واﻹﺣﺗﯾﺎطﺎت</strong></p><p dir="RTL">ﺗﺣدث إﻟﻰ طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ أو اﻟﻣﻣرﺿﺔ ﻗﺑل ﺗﻧﺎول ميكتونورم إكس إل</p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك ﺗﻠف ﻓﻲ اﻷﻋﺻﺎب اﻟﺗﻲ ﺗﺗﺣﻛم ﻓﻲ ﺿﻐط اﻟدم وﻣﻌدل ﺿرﺑﺎت اﻟﻘﻠب وﺣرﻛﺔ اﻷﻣﻌﺎء واﻟﻣﺛﺎﻧﺔ وﻏﯾرھﺎ ﻣن وظﺎﺋف اﻟﺟﺳم (اﻻﻋﺗﻼل اﻟﻌﺻﺑﻲ اﻟﻼإرادي).</p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك ﻣﺷﺎﻛل ﻓﻲ اﻟﻛﺑد.</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﺎن ﻟدﯾك ﻣﺷﺎﻛل ﻓﻲ اﻟﻛﻠﻰ.</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻗﺻور ﺣﺎد ﻓﻲ اﻟﻘﻠب.</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﺎن ﻟدﯾك ﺗﺿﺧم ﻓﻲ ﻏدة اﻟﺑروﺳﺗﺎﺗﺎ.</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻋدوى ﻣﺗﻛررة ﻓﻲ اﻟﻣﺳﺎﻟك اﻟﺑوﻟﯾﺔ.</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﺎن ﻟدﯾك أورام ﻓﻲ اﻟﻣﺳﺎﻟك اﻟﺑوﻟﯾﺔ.</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﺎن ﻟدﯾك زرق اﻟﻌﯾن.</p><p dir="RTL">&middot; إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﺣرﻗﺔ ﻓﻲ اﻟﻣﻌدة وﻋﺳر اﻟﮭﺿم ﺑﺳﺑب اﻟﺗدﻓق اﻟﻌﻛﺳﻲ ﻟﻌﺻﺎرة اﻟﻣﻌدة إﻟﻰ اﻟﺣﻠق (ﻓﺗق ﻓﺟوة ﻣﻊ اﻟﺗﮭﺎب اﻟﻣريء اﻻرﺗﺟﺎﻋﻲ).</p><p dir="RTL">&middot; إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻋدم اﻧﺗظﺎم ﻓﻲ ﺿرﺑﺎت اﻟﻘﻠب.</p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك ﺿرﺑﺎت ﻗﻠب ﺳرﯾﻌﺔ.</p><p dir="RTL">إذا كنت تعاني من أي من هذه الحالات، اتصل بطبيبك سيخبرك ماذا تفعل.</p><p dir="RTL"><strong>الأدوﯾﺔ اﻷﺧرى و ميكتونورم إكس إل</strong></p><p dir="RTL">أﺧﺑر طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ إذا ﻛﻧت ﺗﺗﻧﺎول أو ﺗﻧﺎوﻟت ﻣؤﺧرًا أو ﻗد ﺗﺗﻧﺎول أﯾًﺎ ﻣن اﻷدوﯾﺔ اﻟﺗﺎﻟﯾﺔ ﻷﻧﮭﺎ ﻗد ﺗﺗﻔﺎﻋل ﻣﻊ ميكتونورم إكس إل</p><p dir="RTL">&middot; ﻣﺿﺎدات اﻻﻛﺗﺋﺎب (ﻣﺛل إﯾﻣﯾﺑراﻣﯾن ، ﻛﻠوﻣﯾﺑراﻣﯾن ، أﻣﯾﺗرﯾﺑﺗﯾﻠﯾن).</p><p dir="RTL">&middot; أﻗراص اﻟﻧوم (ﻣﺛل اﻟﺑﻧزودﯾﺎزﯾﺑﯾﻧﺎت).</p><p dir="RTL">&middot; ﻣﺿﺎدات اﻟﻛوﻟﯾن اﻟﺗﻲ ﺗؤﺧذ ﻋن طرﯾق اﻟﻔم أو اﻟﺣﻘن (ﺗﺳﺗﺧدم ﻋﺎدة ﻟﻌﻼج اﻟرﺑو ، ﺗﻘﻠﺻﺎت اﻟﻣﻌدة ﻣﺷﺎﻛل اﻟﻌﯾن أو ﺳﻠس اﻟﺑول).</p><p dir="RTL">&middot; أﻣﺎﻧﺗﺎدﯾن (ﯾﺳﺗﺧدم ﻟﻌﻼج اﻹﻧﻔﻠوﻧزا وﻣرض ﺑﺎرﻛﻧﺳون).</p><p dir="RTL">&middot; ﻣﺿﺎدات اﻟذھﺎن ﻣﺛل ﺑروﻣﺎزﯾن ، أوﻻﻧزاﺑﯾن ، ﻛﯾﺗﯾﺎﺑﯾن (أدوﯾﺔ ﺗﺳﺗﺧدم ﻟﻌﻼج اﻻﺿطراﺑﺎت اﻟذھﺎﻧﯾﺔ ﻣﺛل اﻟﻔﺻﺎم واﻟﻘﻠق).</p><p dir="RTL">&middot; ﻣﻧﺑﮭﺎت ﺑﯾﺗﺎ (أدوﯾﺔ ﺗﺳﺗﺧدم ﻟﻌﻼج اﻟرﺑو).</p><p dir="RTL">&middot; اﻟﻛوﻟﯾﻧﺎت (ﻛﺎرﺑﺎﻛول وﺑﯾﻠوﻛﺎرﺑﯾن).</p><p dir="RTL">&middot; أﯾزوﻧﯾﺎزﯾد (ﻋﻼج ﻟﻣرض اﻟﺳل).</p><p dir="RTL">&middot; ﻣﯾﺗوﻛﻠوﺑراﻣﯾد (ﯾﺳﺗﺧدم ﻟﻌﻼج اﻟﻐﺛﯾﺎن واﻟﻘﻲء).</p><p dir="RTL">&middot; اﻟﻌﻼج اﻟﻣﺗزاﻣن ﻣﻊ اﻟﻣﯾﺛﯾﻣﺎزول (اﻟذي ﯾﺳﺗﺧدم ﻟﻌﻼج ﻓرط ﻧﺷﺎط اﻟﻐدة اﻟدرﻗﯾﺔ) واﻷدوﯾﺔ اﻟﻣﺳﺗﺧدﻣﺔ ﻟﻌﻼج اﻷﻣراض اﻟﻔطرﯾﺔ (ﻣﺛل ﻛﯾﺗوﻛوﻧﺎزول ، إﯾﺗراﻛوﻧﺎزول).</p><p dir="RTL">وﻣﻊ ذﻟك، ﻗد ﯾﻛون ﻣن اﻟﻣﻧﺎﺳب ﻟك أن ﺗﺄﺧذ ميكتونورم إكس إل. ﺳﯾﻛون طﺑﯾﺑك ﻗﺎدرًا ﻋﻠﻰ ﺗﺣدﯾد ﻣﺎ ھو ﻣﻧﺎﺳب ﻟك.</p><p dir="RTL">ﯾرﺟﻰ إﺧﺑﺎر طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ إذا ﻛﻧت ﺗﺗﻧﺎول أو ﺗﻧﺎوﻟت ﻣؤﺧرًا أي أدوﯾﺔ أﺧرى، ﺑﻣﺎ ﻓﻲ ذﻟك اﻷدوﯾﺔ اﻟﺗﻲ ﺗم اﻟﺣﺻول ﻋﻠﯾﮭﺎ ﺑدون وﺻﻔﺔ طﺑﯾﺔ.</p><p dir="RTL"><strong>الحمل واﻟرﺿﺎﻋﺔ واﻟﺧﺻوﺑﺔ</strong></p><p dir="RTL">إذا ﻛﻧت ﺣﺎﻣﻼ أو ﻣرﺿﻌﺔ ، ﺗﻌﺗﻘدﯾن أﻧك ﺣﺎﻣل أو ﺗﺧططﯾن ﻹﻧﺟﺎب طﻔل، اﺳﺄﻟﻲ طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ ﻟﻠﺣﺻول ﻋﻠﻰ اﻟﻣﺷورة ﻗﺑل ﺗﻧﺎول ھذا اﻟدواء.</p><p dir="RTL">ﻻ ﺗﺄﺧذي ميكتونورم إكس إل إذا ﻛﻧت ﺣﺎﻣﻼً أو ﻣن اﻟﻣﺣﺗﻣل أن ﺗﺻﺑﺣﻲ ﺣﺎﻣﻼً أو ﻣرﺿﻌﺔ.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">ﯾﻣﻛن أن ﯾﺳﺑب ميكتونورم إكس إل أﺣﯾﺎﻧﺎ اﻟﻧﻌﺎس وﻋدم وﺿوح اﻟرؤﯾﺔ. ﻻ ﯾﺟوز ﻟك اﻟﻘﯾﺎدة أو ﺗﺷﻐﯾل اﻵﻻت ﺣﺗﻰ ﺗﺗﺄﻛد ﻣن ﻋدم ﺗﺄﺛرك.</p><p dir="RTL"><strong>يحتوي ميكتونورم إكس إل ﻋﻠﻰ ﺳﻛر اﻟﻼﻛﺗوز</strong></p><p dir="RTL">إذا أﺧﺑرك طﺑﯾﺑك أﻧك ﻻ ﺗﺗﺣﻣل ﺑﻌض اﻟﺳﻛرﯾﺎت ، ﻓﺎﺗﺻل ﺑطﺑﯾﺑك ﻗﺑل ﺗﻧﺎول ھذا اﻟدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اﺣرص داﺋﻣًﺎ ﻋﻠﻰ ﺗﻧﺎول ھذا اﻟدواء ﺗﻣﺎﻣًﺎ ﻛﻣﺎ أﺧﺑرك طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ. اﺳﺗﺷر طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ إذا ﻟم ﺗﻛن ﻣﺗﺄﻛدًا.</p><p dir="RTL"><strong>الجرعة الموصى بها</strong></p><p dir="RTL">اﻟﻛﺑﺎر وﻛﺑﺎر اﻟﺳن: اﻟﺟرﻋﺔ اﻟﻣوﺻﻰ ﺑﮭﺎ ﻛﺑﺳوﻟﺔ واﺣدة ﯾوﻣﯾﺎً</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين:</strong></p><p dir="RTL">لا ﯾﻧﺻﺢ ﺑﺎﺳﺗﺧدام&nbsp; ميكتونورم إكس إل ﻟﻸطﻔﺎل.</p><p dir="RTL"><strong>طريقة اﻻﺳﺗﻌﻣﺎل:</strong></p><p dir="RTL">ﺧذ ﻛﺑﺳوﻟﺗك ﻓﻲ ﻧﻔس اﻟوﻗت ﻛل ﯾوم. اﺑﺗﻠﻊ اﻟﻛﺑﺳوﻟﺔ ﻛﺎﻣﻠﺔ ﻣﻊ ﺷرب اﻟﻣﺎء. ﻻ ﺗﺳﺣق أو ﺗﻣﺿﻎ اﻟﻛﺑﺳوﻻت. ﯾﻣﻛﻧك ﺗﻧﺎوﻟﮭﺎ ﻣﻊ اﻟطﻌﺎم أو بدونه.</p><p dir="RTL"><strong>إذا ﺗﻧﺎوﻟت ميكتونورم إكس إل أﻛﺛر ﻣﻣﺎ ﯾﺟب</strong></p><p dir="RTL">إذا ﺗﻧﺎوﻟت ﺑﺎﻟﺧطﺄ أﻛﺛر ﻣن اﻟﺟرﻋﺔ اﻟﻣوﺻوﻓﺔ ﻟك ، ﻓﺎﺗﺻل ﺑﺄﻗرب ﻗﺳم إﺻﺎﺑﺔ أو أﺧﺑر طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ ﻋﻠﻰ اﻟﻔور. ﺗذﻛر أن ﺗﺄﺧذ اﻟﻌﻠﺑﺔ وأي ﻛﺑﺳوﻻت ﻣﺗﺑﻘﯾﺔ ﻣﻌك. ﯾﻣﻛن أن ﺗﺳﺑب اﻟﺟرﻋﺔ اﻟزاﺋدة أﻋراﺿًﺎ ﻣﺛل اﻷرق واﻟدوار واﺿطراﺑﺎت ﻓﻲ اﻟﻛﻼم واﻟرؤﯾﺔ وﺿﻌف اﻟﻌﺿﻼت وﺟﻔﺎف اﻟﻔم وﺳرﻋﺔ ﺿرﺑﺎت اﻟﻘﻠب وﻣﺷﺎﻛل اﻟﺗﺑول.</p><p dir="RTL"><strong>إذا ﻧﺳﯾت أن ﺗﺄﺧذ ميكتونورم إكس إل</strong></p><p dir="RTL">ﻻ ﺗﻘﻠق. ﺑﺑﺳﺎطﺔ اﺗرك ﺗﻠك اﻟﺟرﻋﺔ ﺗﻣﺎﻣًﺎ. ﺛم ﺗﻧﺎول ﺟرﻋﺗك اﻟﺗﺎﻟﯾﺔ ﻓﻲ اﻟوﻗت اﻟﻣﻧﺎﺳب. ﻻ ﺗﺄﺧذ ﺟرﻋﺔ ﻣﺿﺎﻋﻔﺔ ﻟﺗﻌوﯾض اﻟﺟرﻋﺔ اﻟﻣﻧﺳﯾﺔ.</p><p>إذا ﻛﺎن ﻟدﯾك أي أﺳﺋﻠﺔ أﺧرى ﺣول اﺳﺗﺧدام ھذا اﻟدواء ، اﺳﺄل طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ أو اﻟﻣﻣرﺿﺔ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال في كل الأدوية، هذا الدواء يمكن أن يتسبب بأعراض جانبية، بالرغم من أنها قد لا تحدث للجميع. ﯾﻣﻛن ﻟﺟﻣﯾﻊ اﻷدوﯾﺔ أن ﺗﺳﺑب ردود ﻓﻌل ﺗﺣﺳﺳﯾﺔ ﻋﻠﻰ اﻟرﻏم ﻣن ﻧدرة ردود اﻟﻔﻌل اﻟﺗﺣﺳﺳﯾﺔ اﻟﺧطﯾرة. اﻷﻋراض اﻟﺗﺎﻟﯾﺔ ھﻲ اﻟﻌﻼﻣﺎت اﻷوﻟﻰ ﻟﻣﺛل ھذه اﻟﺗﻔﺎﻋﻼت:</p><p dir="RTL">&middot; أي أزﯾز ﻣﻔﺎﺟﺊ أو ﺻﻌوﺑﺔ ﻓﻲ اﻟﺗﻧﻔس أو دوار أو اﻧﺗﻔﺎخ ﻓﻲ اﻟﺟﻔون أو الوجه أو اﻟﺷﻔﺗﯾن أو اﻟﺣﻠق.</p><p dir="RTL">&middot; ﺗﻘﺷﯾر وﺑﺛور ﻓﻲ اﻟﺟﻠد واﻟﻔم واﻟﻌﯾﻧﯾن واﻷﻋﺿﺎء اﻟﺗﻧﺎﺳﻠﯾﺔ.</p><p dir="RTL">&middot; اﻟطﻔﺢ اﻟﺟﻠدي اﻟذي ﯾؤﺛر ﻋﻠﻰ اﻟﺟﺳم كله.</p><p dir="RTL">إذا ظﮭرت ﻟدﯾك أي ﻣن ھذه اﻷﻋراض أﺛﻧﺎء اﻟﻌﻼج ، ﯾﺟب ﻋﻠﯾك اﻟﺗوﻗف ﻋن ﺗﻧﺎول اﻟﻛﺑﺳوﻻت واﻻﺗﺻﺎل ﺑطﺑﯾﺑك ﻋﻠﻰ اﻟﻔور.</p><p dir="RTL">ﻗد ﺗﻌﺎﻧﻲ ﻣن ﻧوﺑﺔ ﺣﺎدة ﻣن زرق اﻟﻌﯾن. إذا ﻛﻧت ﺗرى ﺣﻠﻘﺎت ﻣﻠوﻧﺔ ﺣول اﻷﺿواء أو إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن أﻟم ﺷدﯾد ﻓﻲ أي ﻣن اﻟﻌﯾﻧﯾن وﺣوﻟﮭﺎ، ﻓﯾﺟب ﻋﻠﯾك طﻠب اﻟﻌﻧﺎﯾﺔ اﻟطﺑﯾﺔ ﻋﻠﻰ وجه اﻟﺳرﻋﺔ.</p><p dir="RTL">ﺗم رﺻد اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ اﻟﺗﺎﻟﯾﺔ:</p><p dir="RTL"><strong>شائعة ﺟدًا (ﻗد ﯾﺻﯾب أﻛﺛر ﻣن 1 ﻣن ﻛل 10 أﺷﺧﺎص).</strong></p><p dir="RTL">ﻓم ﺟﺎف</p><p dir="RTL">ﺷﺎﺋﻌﺔ (ﻗد ﺗظﮭر ﻟدى ﺣﺗﻰ 1&nbsp; ﻣن ﻛل 10 أﺷﺧﺎص).</p><p dir="RTL">ﺧﻠل ﻓﻲ اﻟرؤﯾﺔ وﺻﻌوﺑﺔ ﻓﻲ اﻟﺗرﻛﯾز ، إرھﺎق ، ﺻداع ، آﻻم ﻓﻲ اﻟﺑطن ، ﻋﺳر ھﺿم ، إﻣﺳﺎك.</p><p dir="RTL"><strong>ﻏﯾر ﺷﺎﺋﻌﺔ (ﻗد ﺗظﮭر ﻟدى ﺣﺗﻰ 1 ﻣن ﻛل 100 ﺷﺧص)</strong></p><p dir="RTL">اﻟﺷﻌور ﺑﺎﻟﻐﺛﯾﺎن واﻟﻘﻲء ، واﻟدوﺧﺔ ، واﻻرﺗﺟﺎف ، وﻋدم اﻟﻘدرة ﻋﻠﻰ إﻓراغ اﻟﻣﺛﺎﻧﺔ (اﺣﺗﺑﺎس اﻟﺑول)، واﺣﻣرار ، وﺗﻐﯾر ﻓﻲ ﺣﺎﺳﺔ اﻟﺗذوق ، واﻧﺧﻔﺎض ﺿﻐط اﻟدم ﻣﻊ اﻟﻧﻌﺎس، واﻟﺣﻛﺔ ، وﺻﻌوﺑﺔ اﻟﺗﺑول.</p><p dir="RTL"><strong>ﻧﺎدرة (ﻗد ﺗظﮭر ﻟدى ﺣﺗﻰ 1&nbsp; ﻣن ﻛل 1000&nbsp; ﺷﺧص)</strong></p><p dir="RTL">طﻔﺢ ﺟﻠدي.</p><p dir="RTL">ﺳرﻋﺔ ﺿرﺑﺎت اﻟﻘﻠب.</p><p dir="RTL"><strong>ﻧﺎدر ﺟدًا (ﻗد ﯾؤﺛر ﻋﻠﻰ ﺷﺧص واﺣد ﻣن ﺑﯾن 10000&nbsp; ﺷﺧص)</strong></p><p dir="RTL">اﻟﺷﻌور ﺑﺿرﺑﺎت ﻗﻠﺑك واﻷرق واﻻرﺗﺑﺎك.</p><p dir="RTL"><strong>غير ﻣﻌروف (ﻻ ﯾﻣﻛن ﺗﻘدﯾر اﻟﺗردد ﻣن اﻟﺑﯾﺎﻧﺎت اﻟﻣﺗﺎﺣﺔ)</strong></p><p dir="RTL">اﻹﺣﺳﺎس ﺑﺄﺷﯾﺎء ﻏﯾر ﺣﻘﯾﻘﯾﺔ (ھﻠوﺳﺔ).</p><p dir="RTL">اﺿطراب اﻟﻛﻼم</p><p dir="RTL">&nbsp;ﺟﻣﯾﻊ اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ اﻟﻣﺣﺗﻣﻠﺔ ﻋﺎﺑرة وﺗﺗﻼﺷﻰ ﺑﻌد ﺗﻘﻠﯾل اﻟﺟرﻋﺔ أو إﻧﮭﺎء اﻟﻌﻼج ﺑﻌد&nbsp; 1-4 أﯾﺎم ﻛﺣد أﻗﺻﻰ. أﺛﻧﺎء اﻟﻌﻼج طوﯾل اﻷﻣد ، ﯾﺟب ﻣراﻗﺑﺔ إﻧزﯾﻣﺎت اﻟﻛﺑد ، ﻷن اﻟﺗﻐﯾرات اﻟﻌﻛﺳﯾﺔ ﻓﻲ إﻧزﯾﻣﺎت اﻟﻛﺑد ﻗد ﺗﺣدث ﻓﻲ ﺣﺎﻻت ﻧﺎدرة.</p><p dir="RTL">&nbsp;إذا ظﮭرت ﻟدﯾك أي آﺛﺎر ﺟﺎﻧﺑﯾﺔ ، ﺗﺣدث إﻟﻰ طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ. ﯾﺗﺿﻣن ذﻟك أي آﺛﺎر ﺟﺎﻧﺑﯾﺔ ﻣﺣﺗﻣﻠﺔ&nbsp; ﻏﯾر ﻣذﻛورة ﻓﻲ ھذه اﻟﻧﺷرة. ﯾﺟب اﻹﺑﻼغ ﻋن أي ﺣدث ﻣﺷﺗﺑﮫ ﺑﮫ أو ﺳﻠﺑﻲ ﻋﻠﻰ ھذا اﻟﻣﻧﺗﺞ إﻟﻰ Drugsafety@labatec.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p>إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ الطبيب أو مقدم الرعاية الصحية أوالصيدلي<strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot; احفظ ھذا اﻟدواء ﺑﻌﯾدًا ﻋن ﻣﺗﻧﺎول اﻷطﻔﺎل</p><p dir="RTL">&middot; ﻻ ﯾﺟوز ﺗﺧزﯾن اﻟﻌﺑوة ﻓوق 30 درﺟﺔ ﻣﺋوﯾﺔ.</p><p dir="RTL">&middot; اﺣﺗﻔظ ﺑﺎﻟﻛﺑﺳوﻻت ﻓﻲ اﻟﻌﻠﺑﺔ اﻷﺻﻠﯾﺔ ﻟﺣﻣﺎﯾﺗﮭﺎ ﻣن اﻟرطوﺑﺔ.</p><p dir="RTL">&middot; ﻻ ﺗﺳﺗﺧدم ھذا اﻟدواء ﺑﻌد ﺗﺎرﯾﺦ اﻧﺗﮭﺎء اﻟﺻﻼﺣﯾﺔ اﻟﻣدون ﻋﻠﻰ اﻟﻛرﺗون.</p><p dir="RTL">&middot; يشير ﺗﺎرﯾﺦ اﻧﺗﮭﺎء اﻟﺻﻼﺣﯾﺔ إﻟﻰ اﻟﯾوم اﻷﺧﯾر ﻣن ﻧﻔس اﻟﺷﮭر.</p><p dir="RTL">&middot; ﻻ ﺗﺗﺧﻠص ﻣن اﻷدوﯾﺔ ﻓﻲ ﻣﯾﺎه اﻟﺻرف اﻟﺻﺣﻲ أو اﻟﻧﻔﺎﯾﺎت اﻟﻣﻧزﻟﯾﺔ.</p><p dir="RTL">&middot; اﺳﺄل اﻟﺻﯾدﻟﻲ ﻋن ﻛﯾﻔﯾﺔ اﻟﺗﺧﻠص ﻣن اﻷدوﯾﺔ اﻟﺗﻲ ﻟم ﺗﻌد ﺗﺳﺗﺧدﻣﮭﺎ.</p><p dir="RTL">&middot; ﺳﺗﺳﺎﻋد ھذه اﻹﺟراءات ﻓﻲ ﺣﻣﺎﯾﺔ اﻟﺑﯾﺋﺔ</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اﻟﻣﺎدة اﻟﻔﻌﺎﻟﺔ ھﻲ ﺑروﺑﯾﻔرﯾن ھﯾدروﻛﻠورﯾد. ﺗﺣﺗوي ﻛل ﻛﺑﺳوﻟﺔ ﻣﻌدﻟﺔ اﻟﺗﺣرر ﻋﻠﻰ 30 ﻣﻠﻎ ﻣن ﺑروﺑﯾﻔرﯾن ھﯾدروﻛﻠورﯾد.</p><p dir="RTL">اﻟﻣﻛوﻧﺎت اﻷﺧرى ھﻲ ﺣﻣض اﻟﺳﺗرﯾك ، اﻟﺑوﻓﯾدون ، اﻟﻼﻛﺗوز أﺣﺎدي اﻟﮭﯾدرات ، اﻟﺗﻠك ، ﺛﻼﺛﻲ إﯾﺛﯾل ﺳﺗرات ، ﺳﺗﯾرات اﻟﻣﻐﻧﯾﺳﯾوم ، ﻣﯾﺛﺎﻛرﯾﻠﯾك ﺣﻣض ﻣﯾﺛﯾل ﻣﯾﺛﺎﻛرﯾﻼت ﻛوﺑوﻟﯾﻣر ، أﻣوﻧﯾو ﻣﯾﺛﺎﻛرﯾﻼت ﻛوﺑوﻟﯾﻣر ، ﺟﯾﻼﺗﯾن ، ﺛﺎﻧﻲ أﻛﺳﯾد اﻟﺗﯾﺗﺎﻧﯾوم (E 171)، أﻛﺳﯾد اﻟﺣدﯾد اﻷﺣﻣر (E 172)، وأﻛﺳﯾد اﻟﺣدﯾد الأﺻﻔر(E 172)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﻣﺗوﻓر ﻓﻲ اﻟﺻﯾدﻟﯾﺎت ﺑوﺻﻔﺔ طﺑﯾﺔ.</p><p dir="RTL">ﻛﺑﺳوﻻت ميكتونورم إكس إل ﻣﺗوﻓرة ﻓﻲ ﻋﻠب كرتون ذات 7 ( 7 ﻛﺑﺳوﻻت &times; 1) و 28 ( 7 كبسولة &times; 4)</p><p dir="RTL">قد لا یتم تسویق جمیع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">جهة التصنيع:</p><p dir="RTL">ﻟوزان ﻓﺎرﻣﺎ - أﻟﻣﺎﻧﯾﺎ</p><p dir="RTL">جهة تحرير التشغيلات:</p><p dir="RTL">أﺑوﺟﯾﻔﺎ أرزﯾﻧﻣﺗﯾل - أﻟﻣﺎﻧﯾﺎ</p><p dir="RTL">صاحب ترخيص التسويق:</p><p dir="RTL">لاباتيك فارما أس أي، ميرين 1217 (جنيف)، سويسرا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mictonorm® XL 30mg modified release capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The active ingredient is Propiverine hydrochloridum
One modified release capsule contains 30mg of Propiverine hydrochloridum.
For a full list of excipients see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral modified release capsule.
Capsules of size 3, non­ transparent orange cap, non­ transparent white body, contents of capsules shall be white or almost white pellets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Usual dosage</em></p><p>The recommended daily doses are as follows:</p><p>Adults: as a standard dose one capsule (= 30 mg propiverine hydrochloride) once a day is recommended.</p><p><em>Dose adjustment/titration</em></p><p>In patients receiving drugs that are potent flavin-containing monooxygenase (FMO) inhibitors such as methimazole in combination with potent CYP 3A4/5 inhibitors treatment should start with a dose of 15 mg per day. The dose may thereafter be titrated to a higher dose. However, caution should be exercised and physicians should monitor these patients carefully for side effects.</p><p><em>Patients with impaired hepatic function</em></p><p>In patients with mildly impaired hepatic function, there is no need for a dose adjustment; however, treatment should proceed with caution. No studies have been performed to investigate the use of propiverine in patients with moderately or severely impaired hepatic function. Its use is therefore not recommended in these patients.</p><p><em>Patients with impaired renal function</em></p><p>In patients with mild or moderate impairment of renal function, no dose adjustment is required.</p><p><em>Elderly patients</em></p><p>Generally there is no special dose regimen for the elderly.</p><p><em>Children and adolescents</em></p><p>Due to a lack of data, this product should not be used in children.</p><p><em>Mode of administration</em></p><p>Capsules. For oral use.</p><p>Do not crush or chew the capsules.</p><p>There is no clinically relevant effect of food on the pharmacokinetics of propiverine.</p><p>Accordingly, there is no particular recommendation for the intake of propiverine in relation to food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The drug is contraindicated in patients who have demonstrated hypersensitivity to the active substance or to any of the excipients and in patients suffering from one of the following disorders: 
• obstruction of the bowel
• significant degree of bladder outflow obstruction where urinary retention may be anticipated
• myasthenia gravis
• intestinal atony
• severe ulcerative colitis
• toxic megacolon
• uncontrolled angle closure glaucoma
• moderate or severe hepatic impairment
• tachyarrhythmias
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The drug should be used with caution in patients suffering from:</p><p>&bull; autonomic neuropathy</p><p>&bull; renal impairment</p><p>&bull; hepatic impairment</p><p>Symptoms of the following diseases may be aggravated following administration of the drug:</p><p>&bull; severe congestive heart failure (classe NYHA IV)</p><p>&bull; prostatic enlargement</p><p>&bull; hiatus hernia with reflux oesophagitis</p><p>&bull; cardiac arrhythmia</p><p>&bull; tachycardia</p><p>Propiverine, like other anticholinergics, induces mydriasis. Therefore, the risk to induce acute angle-closure glaucoma in individuals predisposed with narrow angles of the anterior chamber may be increased. Drugs of this class, including propiverine, have been reported to induce or precipitate acute angle-closure glaucoma.</p><p>Pollakiuria and nocturia due to renal disease or congestive heart failure, as well as organic bladder diseases (e.g. urinary tract infections, malignancy), should be ruled out prior to treatment.</p><p>Patients with galactose intolerance, total lactase deficiency or glucose-galactose malabsorption syndrome (rare hereditary diseases) should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pharmacokinetic interactions</em></p><p>Pharmacokinetic interactions are possible with other drugs metabolised by cytochrome P450 3A4 (CYP 3A4). However, a very pronounced increase of concentrations for such drugs is not expected as the effects of propiverine are small compared to classical enzyme inhibitors (e.g. ketoconazole or grapefruit juice). Propiverine may be considered as weak inhibitor of CYP 3A4. Pharmacokinetic studies with patients concomitantly receiving potent CYP 3A4 inhibitors such as azole antifungals (e.g. ketoconazole, itraconazole) or macrolide antibiotics (e.g. erythromycin, clarithromycin) have not been performed.</p><p><em>Enzyme inhibitors</em></p><p>Patients receiving concomitant treatment with drugs that are potent inhibitors of CYP 3A4 combined with methimazole:</p><p>In patients receiving drugs that are potent flavin-containing monooxygenase (FMO) inhibitors such as methimazole in combination with potent CYP 3A4/5 inhibitors treatment should start with a dose of 15 mg per day. The dose may thereafter be titrated to a higher dose. However, caution should be exercised and physicians should monitor these patients carefully for side effects.</p><p><em>Effect of Mictonorm XL modified-release capsules on other medicinal products</em></p><p>- Increased effects due to concomitant medication with tricyclic antidepressants (e. g. imipramine), tranquillisers (e.g. benzodiazepines), anticholinergics (if applied systemically), amantadine, neuroleptics (e. g. phenothiazines) and beta-adrenoceptor agonists (beta-sympathomimetics).</p><p>- Decreased effects due to concomitant medication with cholinergic drugs.</p><p>- Reduced blood pressure in patients treated with isoniazid.</p><p>- The effect of prokinetics such as metoclopramide may be decreased.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>There are insufficient data from use in pregnant women.</p><p>Studies in animals have shown reproductive toxicity (more precise data under the heading &quot;Preclinical data&quot;).</p><p>This medicine is not recommended during pregnancy.</p><p><strong>Lactation</strong></p><p>It is unknown whether propiverine or metabolites are excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of propiverine or metabolites in milk. A risk to the newborn or infant cannot be excluded.</p><p>A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from propiverine therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p><strong>Fertility</strong></p><p>There are no human data on the effect of propiverine on fertility.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>Propiverine may produce drowsiness and blurred vision. This may impair the patient&rsquo;s ability to exert activities that require mental alertness such as operating a motor vehicle or other machinery, or to exert hazardous work while taking this drug.</p><p>Sedative drugs may enhance the drowsiness caused by propiverine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Within each system organ class, the undesirable effects are ranked under heading of frequency using the following convention:</p><p>Very common (&ge;1/10)</p><p>Common (&ge;1/100 to &lt;1/10)</p><p>Uncommon (&ge;1/1000 to &lt;1/100)</p><p>Rare (&ge;1/10 000 to &lt;1/1000)</p><p>Very rare (&lt;1/10 000)</p><p>Not known (cannot be estimated from the available data).</p><p>All undesirable effects are transient and recede after a dose reduction or termination of the therapy after maximum 1-4 days.</p><p><em>Immune system disorders</em></p><p>Rare: hypersensitivity</p><p><em>Psychiatric disorders</em></p><p>Very rare: restlessness, confusion</p><p>Not known: hallucination</p><p><em>Nervous system disorders</em></p><p>Common: headache</p><p>Uncommon: tremor, dizziness, dysgeusia</p><p>Not known: speech disorder</p><p><em>Eye disorders</em></p><p>Common: accommodation disorder, visual impairment</p><p><em>Cardiac disorders</em></p><p>Rare: tachycardia</p><p>Very rare: palpitation</p><p><em>Vascular disorders</em></p><p>Uncommon: decreased blood pressure with drowsiness, flushing</p><p><em>Gastrointestinal disorders</em></p><p>Very common: dry mouth</p><p>Common: constipation, abdominal pain, dyspepsia</p><p>Uncommon: nausea/vomiting</p><p><em>Skin and subcutaneous tissue disorders</em></p><p>Uncommon: pruritus</p><p>Rare: rash</p><p><em>Renal and urinary disorders</em></p><p>Uncommon: urinary retention, bladder and urethral symptoms</p><p><em>General disorders and administration site conditions</em></p><p>Common: fatigue</p><p>Description of certain undesirable effects</p><p>During long-term therapy hepatic enzymes should be monitored, because reversible changes of liver enzymes might occur in rare cases.</p><p>&nbsp;</p><p>- To report any side effect(s)</p><p>&bull; Saudi Arabia</p><p>NPC contact information Saudi Arabia:</p><p>The National Pharmacovigilance Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966112057662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p>&bull; Other GCC states</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Signs and symptoms</em></p><p>Overdose with the muscarinic receptor antagonist propiverine can potentially result in severe anticholinergic effects. Peripheral and central nervous system disturbances may occur, such as:</p><p>- severe dry mouth</p><p>- bradycardia, possibly leading to tachycardia in the further course</p><p>- mydriasis and accommodation disorder</p><p>- urinary retention</p><p>- inhibition of intestinal motility</p><p>- restlessness, confusion, hallucination, confabulation</p><p>- dizziness, nausea, speech disorder, muscular weakness</p><p><em>Treatment</em></p><p>- In the event of overdose with propiverine the patient should be treated with activated charcoal suspension with plenty amount of water.</p><p>- Gastric lavage should only be taken into consideration with protective intubation, use of an oiled tube (dryness of mucosa) and if performed within 1 hour after ingestion of propiverine. Vomiting must not be induced.</p><p>- Forced diuresis or hemodialysis is not effective to enhance the renal elimination.</p><p>- In case of severe central anticholinergic effects such as hallucinations or pronounced excitation antidote treatment with physostigmine can be attempted.</p><p>- Convulsion or pronounced excitation: treatment with benzodiazepines</p><p>- Respiratory insufficiency: treatment with artificial respiration</p><p>- Urinary retention: treatment with catheterization</p><p>- Mydriasis: treatment with pilocarpine eye drops and/or darkening of the patient&rsquo;s room.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal models propiverine hydrochloride causes a dose-dependent decrease of the intravesical pressure and an increase in bladder capacity.</p><p>The effect is based on the sum of the pharmacological properties of propiverine and three active urinary metabolites as shown in isolated detrusor strips of human and animal origin.</p><p><strong>Clinical efficacy</strong></p><p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Propiverine is nearly completely absorbed from the gastrointestinal tract. It undergoes extensive first pass metabolism. Effects on urinary bladder smooth muscle cells are due to the parent compound and three active metabolites as well, which are rapidly excreted into the urine.</p><p><em>Absorption</em></p><p>After oral administration of Mictonorm XL , propiverine is absorbed from the gastrointestinal tract with maximal plasma concentrations reached after 9,9 hours. The mean absolute bioavailability of Mictonorm XL is 60,8 &plusmn; 17,3% [arithmetic mean value &plusmn; SD for ASC0-&infin; (per os) / ASC0-&infin; (i.v.)].</p><p>Food does not influence the pharmacokinetics of propiverine. The bioavailability of propiverine after the meal was 99 % compared to the fasting conditions. Administration of the modified-release capsule leads to a peak plasma concentration (Cmax) of about 70 ng/ml reached within 9,5 hours after administration. The Cmax values for the main metabolite propiverine-N-oxide were slightly increased by food (f = 1,26) whereas the extent of absorption was unchanged. Propiverine-N-oxide showed for all pharmacokinetic parameters 90 % confidence intervals within the acceptance ranges. An adjustment of dose in relation to food intake is not required.</p><p><em>Distribution</em></p><p>After administration of Mictonorm XL, steady state is reached after 4 to 5 days at a higher concentration level than after single dose application (C<sub>average</sub> = 71 ng/ml).</p><p>The volume of distribution was estimated in 21 healthy volunteers after intravenous administration of propiverine hydrochloride to range from 125 to 473 l (mean 279 l) indicating, that a large amount of available propiverine is distributed to peripheral compartments. The binding to plasma proteins is 90 - 95 % for the parent compound and about 60 % for the main metabolite.</p><p><em>Pharmacokinetic characteristics (geometric mean, &plusmn; SD, range) of propiverine in 10 healthy volunteers after single dose administration of Mictonorm XL and propiverine hydrochloride 45 mg modified-release capsules:</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Dose [mg]</strong></p></td><td style="vertical-align:top"><p><strong>30</strong></p></td><td style="vertical-align:top"><p><strong>45 </strong></p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>ASC <sub>0-&infin;</sub> [ng&times;h/ml]</p></td><td style="vertical-align:top"><p>1378</p><p>(903, 2104)</p></td><td style="vertical-align:top"><p>1909</p><p>(1002, 3639)</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> [ng/ml]</p></td><td style="vertical-align:top"><p>60,6</p><p>(41,5, 88,6)</p></td><td style="vertical-align:top"><p>80,0</p><p>(41.8, 152.1)</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>t<sub>1/2 </sub>[h]</p></td><td style="vertical-align:top"><p>14,2</p><p>(10,8, 18,6)</p></td><td style="vertical-align:top"><p>16,3</p><p>(13,9, 19,2)</p></td><td>&nbsp;</td></tr><tr><td rowspan="2" style="vertical-align:top"><p>t<sub>max</sub> [h]</p></td><td rowspan="2" style="vertical-align:top"><p>9,9</p><p>&plusmn; 2,4</p></td><td rowspan="2" style="vertical-align:top"><p>9,9</p><p>&plusmn; 2,4</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><em>Plasma concentrations of propiverine in 10 healthy volunteers after single dose administration of Mictonorm XL and propiverine hydrochloride 45 mg modified-release capsules: </em></p><p><img src="data:image/png;base64,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" alt="" width="390" height="277" vspace="0" hspace="0" border="0" style="width:390px;height:277px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><em>Steady state characteristics of propiverine following multiple-dose administration to 24 healthy volunteers of propiverine hydrochloride 45 mg modified-release capsules once daily for 7 days:</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>geometric mean</strong></p></td><td style="vertical-align:top"><p><strong>range or &plusmn; SD</strong></p></td></tr><tr><td style="vertical-align:top"><p>ASC <sub>0-24h</sub> [ng/h/ml]</p></td><td style="vertical-align:top"><p>1711</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1079, &nbsp; 2713</p></td></tr><tr><td style="vertical-align:top"><p>PTF* &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;[%]</p></td><td style="vertical-align:top"><p>109,4</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 81.2, &nbsp;&nbsp; 147,5</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>average</sub>&nbsp; [ng/ml]</p></td><td style="vertical-align:top"><p>71</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 45,0, &nbsp;&nbsp; 113,0</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;[ng/ml]</p></td><td style="vertical-align:top"><p>105</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 71, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 155</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>min</sub> &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;[ng/ml]</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 42</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>1/2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</sub>[h]</p></td><td style="vertical-align:top"><p>20,4</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12,8, &nbsp;&nbsp; 32,3</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>max</sub> &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;[h]</p></td><td style="vertical-align:top"><p>7,3</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &plusmn; 2,5</p></td></tr></tbody></table><p><em>* PTF: peak-trough fluctuation</em></p><p>&nbsp;</p><p><em>Plasma concentrations of propiverine on day 7 and trough levels during treatment following multiple-dose administration of propiverine hydrochloride 45 mg modified-release capsules once daily for 7 days: </em></p><p><strong><img src="data:image/png;base64,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" alt="" width="397" height="277" vspace="0" hspace="0" border="0" style="width:397px;height:277px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p><em>Metabolism</em></p><p>Propiverine is extensively metabolised by intestinal and hepatic enzymes. The primary metabolic route involves the oxidation of the piperidyl-N and is mediated by CYP 3A4 and flavin-containing monooxygenases (FMO) 1 and 3 and leads to the formation of the much less active N-oxide, the plasma concentration of which greatly exceeds that of the parent substance. Four metabolites were identified in urine; three of them are pharmacologically active and may contribute to the therapeutic efficacy.</p><p>In vitro there is a slight inhibition of CYP 3A4 and CYP 2D6 detectable which occurs at concentrations exceeding therapeutic plasma concentrations 10- to 100-fold.</p><p><em>Elimination</em></p><p>Following administration of 30 mg oral dose of <sup>14</sup>C- propiverine hydrochloride to healthy volunteers, 60&nbsp;% of radioactivity was recovered in urine and 21 % was recovered in faeces within 12 days. Less than 1 % of an oral dose is excreted unchanged in the urine. Mean total clearance after single dose administration of 30 mg is 371 ml/min (191 &ndash; 870 ml/min).</p><p><em>Linearity/ non-linearity</em></p><p>Pharmacokinetic parameters of propiverine following oral administration of 10 &ndash; 45 mg of propiverine hydrochloride are linearly related to dose.</p><p><em>Correlation between the oral dose of extended release propiverine and the resulting AUC 0-&infin;:</em></p><p><img src="data:image/png;base64,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" alt="" width="407" height="277" vspace="0" hspace="0" border="0" style="width:407px;height:277px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><em>Correlation between the oral dose of extended release propiverine and the resulting Cmax:</em></p><p><img src="data:image/png;base64,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" alt="" width="393" height="277" vspace="0" hspace="0" border="0" style="width:393px;height:277px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><em>Kinetics in specific patient groups</em></p><p><em>Hepatic impairment</em></p><p>There were similar steady state pharmacokinetics in 12 patients with mild to moderate impairment of liver function due to fatty liver disease as compared to 12 healthy controls. No data are available for severe hepatic impairment.</p><p><em>Renal impairment</em></p><p>Severe renal impairment does not significantly alter the disposition of propiverine and its main metabolite, propiverine-N-oxide, as deduced from a single dose study in 12 patients with creatinine clearance &lt; 30 ml/min. No dose adjustment is to be recommended.</p><p><em>Elderly patients</em></p><p>The comparison of trough plasma concentrations during steady state reveals no difference between older patients (60 tu 85 years, mean 68 years) and young healthy subjects. The ratio of parent drug to metabolite remains unchanged in older patients indicating the metabolic conversion of propiverine to its main metabolite, propiverine-N-oxide, not to be an age-related or limiting step in the overall excretion. As bioequivalence of propiverine hydrochloride 15 mg coated tablets administered 3 times a day and propiverine hydrochloride 45 mg coated tablets once a day was established in a good clinical practice compliant study the same can be concluded for Mictonorm XL 30 mg.</p><p><em>Glaucoma patients</em></p><p>The treatment with Mictonorm XL will not lead to an increase of intraocular pressure in patients with open angle glaucoma and in patients with treated (controlled) angle closure glaucoma. This was shown in two placebo-controlled studies with propiverine hydrochloride 15 mg coated tablets administered 3 times a day for 7 days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In long term oral dose studies in two mammalian species the main treatment related effect were changes in the liver (including elevation of hepatic enzymes). These were characterised by hepatic hypertrophy and fatty degeneration. The fatty degeneration was reversible upon cessation of treatment.</p><p>No effects on male and female fertility and reproduction behaviour were observed in toxicological studies with rats.</p><p>In animal studies, skeletal retardation in the offspring occurred when the drug was administered orally at high doses to pregnant females. In lactating mammals propiverine was excreted into the milk.</p><p>There was no evidence of mutagenicity. The carcinogenicity study in mice demonstrated an increased incidence of hepatocellular adenoma and carcinoma in high dose males. In the rat carcinogenicity study hepatocellular adenoma, kidney adenoma and urinary bladder papilloma has been demonstrated in high dose male rats, while in female animals endometrial stromal polyps were increased at the high dose levels. Both the rat and mouse tumours were considered to be species specific and therefore not of clinical relevance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pellets</p><p>- Citric acid</p><p>- Povidone</p><p>- Lactose monohydrate 5.7 mg</p><p>- Talc</p><p>- Triethyl citrate</p><p>- Magnesium Stearate</p><p>- Methacrylic acid - methyl methacrylate copolymer (1:1)</p><p>- Methacrylic acid - methyl methacrylate copolymer (1:2)</p><p>- Ammonio methacrylate copolymer type A</p><p>- Ammonio methacrylate copolymer type B</p><p>- Acetone</p><p>- Isopropyl Alcohol</p><p>- Purified water</p><p>Capsule</p><p>- Gelatin</p><p>- Titanium dioxide E171</p><p>- Red Iron Oxide E 172</p><p>- Yellow Iron Oxide E 172</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original package to protect from moisture.</p><p>Keep out of reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/aluminium blister</p><p>The bottom foil is a cold-formable aluminium foil composed of 3 separate layers:</p><p>Polyamide: 25 &mu;m</p><p>Aluminum: 47 &mu;m</p><p>PVC: 60 &mu;m</p><p>This type ensures an excellent protection against environmental moisture.</p><p>The cover foil used is an aluminium foil with a thickness of 20 &mu;m which is protective lacquered and suitable for sealing against PVC.</p><p>&nbsp;</p><p>- Pack size: 28 modified release capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LABATEC-PHARMA S.A., 
CH-1217, Meyrin (Geneva), Switzerland.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>